FBN1 and obesity disorder: Finally, Wang et al. concluded that “Asprosin plays a pathogenetic role in insulin resistance [...] asprosin is involved in the onset of obesity and may be a new biomarker of insulin resistance [...] asprosin might serve as a risk factor associated with the development of diabetes mellitus type 2.